Bayer Faces Billions in Payouts

Jury orders Bayer to pay $100 million over PCBs in Washington school
A Washington jury on Tuesday ordered Bayer to pay $100 million to four people who say they were sickened by toxic chemicals known as PCBs at a Seattle-area school, but found the company was not liable for injuries alleged by 11 others.
Bayer Says It Was Told by Jury to Pay $100 Million Over Toxic Chemicals
Bayer AG was told by a jury to pay $100 million to four people at a Seattle-area school who said their exposure at the facility to toxic chemicals made by the company’s Monsanto unit caused brain damage and other injuries.
Bayer faces billions in payouts for half century-old toxic mess
Bayer is facing billions of dollars in exposure from a growing number of lawsuits over PCB products. Read more at straitstimes.com.
Bayer Hit with $100 Million Verdict Over Toxic PCB Exposure
Bayer AG faces a $100 million jury verdict over PCB exposure at a Seattle school amid ongoing legal challenges related to toxic chemicals.
Bayer must pay $100 million in latest trial over PCBs in Washington school, jury finds
By Brendan Pierson and Dietrich Knauth (Reuters) -A Washington state jury on Tuesday ordered Bayer to pay $100 million to four people who say they were sickened by toxic chemicals known as PCBs at a Seattle-area school,
Bayer Hit With $100 Million Verdict Over School’s Toxic PCBs (2)
Bayer AG was told by a jury to pay $100 million to four people at a Seattle-area school who said their exposure at the facility to toxic chemicals made by the company’s Monsanto unit caused brain damage and other injuries.
Bayer pharma chief sees no big acquisitions in near future
Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...
The Western Producer7m
Bayer introduces FieldView Drive 2.0 at Crop Production Show 2025
Bayer used the Western Canadian Crop Production Show in Saskatoon this week to introduce Prairie farmers to its new FieldView ...
Bayer’s Head of Pharma Oelrich Expects Business to Return to Growth in 2027
Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...
Bayer | Morning Blend
As we usher in 2025, it’s the perfect time to prioritize health and wellness. Registered Dietitian and Nutritionist Kelly ...
Cutting Middle Management: Bayer's Costly Experiment One Year Later
In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.
Bayer plant doch keine Pharma-Großdeals, Fokus Schuldenabbau
Mit Blick auf die Neuausrichtung der Medikamentenpipeline von Bayer hatte Pharma-Chef Stefan Oelrich im letzten Januar ...
Bayer Leverkusen edge Mainz 1-0 for seventh league win in a row
Champions Bayer Leverkusen battled past Mainz 05 with a 1-0 win coming courtesy of a superb Alex Grimaldo free kick on ...
Bayer to Scale Back Health Dealmaking Amid Push to Pay Down Debt
Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...